Drugs / KFD1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06768697 | Dec 2024 → Dec 2025 overdue | COVID-19 | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KFD1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06768697 ↗ |
| Modality | Protein / enzyme biologic | “recombinant flagellin protein” NCT06768697 ↗ |
| Route | Intranasal | “nasal spray” NCT06768697 ↗ |